Market research
YBOC.F Tenax Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 245K
- P/E ratio
- Not available
- Analyst target
- 4.75
- Dividend yield
- 0.0%
- Beta
- 2.13
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 245K
- P/E ratio
- Not available
- Analyst target
- 4.75
- Dividend yield
- 0.0%
- Beta
- 2.13
About
About Tenax Therapeutics, Inc
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the YBOC.F discussion.
5 years, 5 months ago
Tenax Therapeutics, Inc is currently in a long term uptrend where the price is trading 8.8% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Tenax Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 1.4% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 15.3% to $-2M since the same quarter in the previous year.
Based on the above factors, Tenax Therapeutics, Inc gets an overall score of 2/5.